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Fluorescence anisotropyn important member of the G-protein coupled receptor family, and is involved in
the generation and modulation of a variety of cognitive, behavioral, and developmental functions. We have
monitored the ligand binding of the human serotonin1A receptor stably expressed in CHO cells (termed CHO-
5-HT1AR) following treatment with sphingomyelinase (SMase), an enzyme that speciﬁcally catalyzes the
hydrolysis of sphingomyelin into ceramide and phosphorylcholine. Our results show, for the ﬁrst time, that
the speciﬁc ligand binding activity of the serotonin1A receptor in membranes isolated from CHO-5-HT1AR
cells is increased upon sphingomyelinase treatment. Saturation binding analysis reveals increase in binding
afﬁnity of the receptor under these conditions. This is accompanied by a reduction in membrane order, as
monitored by ﬂuorescence anisotropy of the membrane probe 1-[4-(trimethylammonio)phenyl]-6-phenyl-
1,3,5-hexatriene (TMA-DPH) in intact cells. These results represent the ﬁrst report on the effect of
sphingomyelinase treatment on the ligand binding activity of this important neurotransmitter receptor.
© 2008 Elsevier B.V. All rights reserved.Sphingolipids are ubiquitous constituents of eukaryotic cell
membranes and constitute ∼10–20% of membrane lipids [1]. Sphin-
golipids are recognized as diverse and dynamic regulators of a
multitude of cellular processes. The sphingoid base, ceramide and
other intermediates of sphingolipid metabolism are known to act as
signaling molecules in mediating cell cycle control, differentiation,
stress response and apoptosis. The distribution of sphingolipids in the
plasma membrane appears to be heterogeneous, and it has been
postulated that sphingolipids and cholesterol localize in laterally
segregated lipid domains (sometimes termed as ‘lipid rafts’) [2,3].
Serotonin receptors represent one of the largest, evolutionarily
ancient, conserved family of seven transmembrane G-protein coupled
receptors (GPCRs) [4,5]. The G-protein coupled serotonin1A (5-HT1A)
receptor is the best characterized among the 14 subtypes of serotonin
receptors [6]. Serotonin1A receptors appear to play a key role in the
generation and modulation of various cognitive, behavioral and
developmental functions [6,7]. The serotonin1A receptor agonists [8]
and antagonists [9] represent major classes of molecules with
potential therapeutic effects in anxiety- or stress-related disorders.
Interestingly, mutant (knockout) mice lacking the serotonin1A recep-
tor exhibit enhanced anxiety-related behavior, and represent an
important animal model for the analysis of complex traits such as
anxiety disorders and aggression in higher animals [10,11]. In view of+91 40 2716 0311.
).
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membrane protein, its interaction with the surrounding lipid
environment assumes greater signiﬁcance in modulating the function
of the receptor in healthy and diseased states. Previous work from our
laboratory has shown the requirement of membrane cholesterol in the
function of this important neurotransmitter receptor (recently
reviewed in [12,13]). In the overall context of the role of sphingolipids
(along with cholesterol) in the formation and maintenance of
membrane domains [2,3], and keeping in mind the relevance of
sphingolipids in the nervous system [14,15], we monitored the effect
of sphingomyelinase treatment on the ligand binding activity of the
human serotonin1A receptor stably expressed in CHO cells (termed
CHO-5-HT1AR) (described earlier [16]). It should be mentioned here
that the effect of sphingolipids on ligand binding function of the
serotonin7 receptor has recently been reported [17].
Sphingomyelinases are enzymes that speciﬁcally catalyze the
hydrolysis of sphingomyelin into ceramide and phosphorylcholine
[18,19]. CHO-5-HT1AR cells were treated with different concentrations
of sphingomyelinase (SMase) (either 25 or 50 mU/ml) for 90 min in D-
MEM/F-12 medium under serum free condition. Enzyme treatment
was terminated by washing off the medium containing enzyme with
phosphate buffered saline (PBS) and the cells were collected for
further analysis. Sphingomyelin levels of CHO-5-HT1AR cells with or
without sphingomyelinase treatment were quantitated by thin layer
chromatography of total lipids (extracted according to Bligh and Dyer
[20]), using chloroform/methanol/water (65:25:4, v/v/v) as the
solvent system. The TLC plate was sprayed with a solution of 0.01%
(w/v) primuline prepared in acetone [21] and the lipid bands were
Fig. 1. Estimation of sphingomyelin content of control and sphingomyelinase treated
CHO-5-HT1AR cells. Sphingomyelinase treatment was carried out as described in the
text. Values are expressed as percentages of sphingomyelin content of untreated
(control) cells. Data shown are means±S.E. of duplicate points from at least three
independent measurements. See text for other details.
Fig. 3. Fluorescence anisotropy measurements of the membrane probe TMA-DPH in
control and sphingomyelinase treated CHO-5-HT1AR cells. Sphingomyelinase treatment
was carried out as described in the text. Data shown are means±S.E. of duplicate points
from three independent measurements (⁎ corresponds to pb0.05; the change in
ﬂuorescence anisotropy was tested against the corresponding value obtained with
untreated (control) cells). See text for other details.
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location of that of the sphingomyelin standard on the TLC plate were
scraped out and the lipids were re-extracted. The extract was dried,
and the concentration of lipid phosphate was determined subsequent
to total digestion by perchloric acid [22] using Na2HPO4 as standard.
Fig. 1 shows the reduction in the sphingomyelin content as a result of
sphingomyelinase treatment. There is ∼53% reduction in sphingomyelin
content when cells were treated with 2 mU/ml of sphingomyelinase,
which reduces to ∼75% when 50mU/ml of sphingomyelinasewas used.
Similar extents of reduction in sphingomyelin content have previously
been reported under certain conditions [23,24].
We further monitored the effect of sphingomyelinase treatment on
the speciﬁc binding of the agonist [3H]8-OH-DPAT (8-hydroxy-2(di-N-
propylamino)tetralin) to the serotonin1A receptor in cell membranes
prepared from CHO-5-HT1AR cells with or without treatment. Cell
membrane preparation and receptor binding assays were carried out
as described earlier [16]. Total protein concentration in cell mem-
branes was determined using Bicinchoninic acid (BCA) reagent [25].
Fig. 2 shows change in the speciﬁc binding of the agonist [3H]8-OH-
DPAT to the serotonin1A receptor upon treatment with sphingomye-
linase. Interestingly, the speciﬁc agonist binding increases by ∼40%
upon sphingomyelinase treatment, irrespective of the enzyme con-
centration used. To the best of our knowledge, this is the ﬁrst reportFig. 2. Speciﬁc binding of the agonist [3H]8-OH-DPAT to serotonin1A receptors in
membranes isolated from control and sphingomyelinase treated CHO-5-HT1AR cells.
Sphingomyelinase treatment was carried out as described in the text. Values are
expressed as percentages of speciﬁc agonist binding obtained in membranes isolated
from untreated (control) cells. Data represent means±S.E. of duplicate points from at
least eight independent measurements. See text for other details.describing change in speciﬁc agonist binding activity of the
serotonin1A receptor upon sphingomyelinase treatment. The speciﬁc
[3H]8-OH-DPAT binding (%) is normalized to the amount of total
protein used in the assay. Although the total protein content varied in
different assays, control experiments reported before showed speciﬁc
binding to be linear with protein content [16].
The observed increase in speciﬁc ligand binding activity due to
modulation in sphingomyelin (or ceramide) level could be because of
an alteration in overall membrane organization (order). In order to
monitor whether there is a change in membrane order upon
sphingomyelinase treatment, ﬂuorescence anisotropy measurements
were carried out on cell suspensions using the membrane probe TMA-
DPH, which is a derivative of DPH with a cationic moiety attached to
the para position of one of the phenyl rings [26]. TMA-DPH has
previously been shown to speciﬁcally label plasma membranes of
intact living cells [27]. Fluorescence anisotropy measurements were
carried out as described earlier [28] with some modiﬁcations.
Fluorescence anisotropy measured using probes such as TMA-DPH,
is correlated to its rotational diffusion [29], which is sensitive to the
packing in the membrane interfacial region. Excitation and emission
wavelengths were set at 358 and 430nm. Excitation and emission slitsFig. 4. Saturation binding analysis of speciﬁc [3H]8-OH-DPAT binding to serotonin1A
receptors in membranes isolated from untreated (control) and sphingomyelinase
treated CHO-5-HT1AR cells. Representative plots are shown for speciﬁc [3H]8-OH-DPAT
binding with increasing concentrations of free [3H]8-OH-DPAT under control (––○––)
and 25 mU/ml (___●___) sphingomyelinase treated conditions. The curves are non-linear
regression ﬁts to the experimental data using Graphpad Prism software. See text and
Table 1 for other details.
Table 1
Effect of sphingomyelinase treatment on speciﬁc [3H]8-OH-DPAT binding parametersa
Treatment Kd (nM) Bmax (pmol/mg)
Control 0.61±0.04 0.42±0.03
25 mU/ml 0.47±0.01 0.45±0.02
50 mU/ml 0.43±0.05 0.39±0.02
a Binding parameters were calculated by analyzing saturation binding isotherms
with a range (0.1–7.5 nM) of radiolabeled [3H]8-OH-DPAT using Graphpad Prism
software. The data represent the means±S.E. of duplicate points from three
independent measurements. See text for other details.
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treated with sphingomyelinase, were lifted from the surface using
0.25 mM EDTA in phosphate buffered saline. The optical density of the
samples measured at 358 nmwas ∼0.1 corresponding to cell density of
∼3×105 cells/ml. Higher cell concentrations were avoided as they could
induce depolarization effects due to the scattering of the emitted light
[28]. The concentration of TMA-DPH in the samples was 0.5 μM.
Fluorescence anisotropymeasurementswere performed using aHitachi
polarization accessory at room temperature (∼23°C). Anisotropy values




where IVV and IVH are the measured ﬂuorescence intensities (after
appropriate background subtraction) with the excitation polarizer
vertically oriented and the emission polarizer vertically and horizon-
tally oriented, respectively. G is the grating correction factor and is
equal to IHV/IHH. Fig. 3 shows the change in ﬂuorescence anisotropy of
TMA-DPH in untreated (control) and sphingomyelinase treated CHO-
5-HT1AR cells. Since the rate of internalization of TMA-DPH is
relatively slow [27], these anisotropy values represent organization
in the cellular plasma membranes. The ﬂuorescence anisotropy of
TMA-DPH appears to decrease signiﬁcantly upon sphingomyelinase
treatment. The apparent reduction in anisotropy was ∼14% upon
treatment with 50 mU/ml sphingomyelinase.
Saturation binding assays were carried out with increasing
concentrations (0.1–7.5 nM) of the radiolabeled agonist [3H]8-OH-
DPAT as described previously [16]. The protein content for the
saturation binding assays was in the range of 40–50 μg. Binding data
was analyzed as described previously [30]. The dissociation constant
(Kd) and maximum binding sites (Bmax) were calculated by non-linear
regression analysis of binding data using Graphpad Prism software
version 4.00 (San Diego, CA). Data obtained after regression analysis
were used to plot graphs with GRAFIT program version 3.09b
(Erithacus Software, Surrey, U.K.). Saturation binding analysis,
shown in Fig. 4 and Table 1, with the agonist [3H]8-OH-DPAT binding
carried out with membranes isolated from control and sphingomye-
linase treated CHO-5-HT1AR cells reveals that the increase in ligand
binding can primarily be attributed to an increase in the afﬁnity of
ligand binding (up to ∼30%, pb0.05 using Graphpad Prism software)
with no signiﬁcant change in total binding sites.
Taken together, our results show that the speciﬁc ligand binding
activity of the serotonin1A receptor in membranes isolated from CHO-
5-HT1AR cells increases upon sphingomyelinase treatment due to an
increase in the afﬁnity of ligand binding. This could be due to the
reduction in the cellular sphingomyelin content or the resultant
increase in ceramide content, or both. The increase in ligand binding
activity is accompanied by a reduction in membrane order, as
monitored by ﬂuorescence anisotropy of TMA-DPH in intact cells.
We have earlier reported that membrane cholesterol is required in
maintaining ligand binding activity of the serotonin1A receptor
[12,30]. We report here, for the ﬁrst time, that sphingolipids
(sphingomyelin and ceramide) are important for ligand binding
activity of the serotonin1A receptor. These results assume relevancein the backdrop of the role of sphingolipids, in conjunction with
cholesterol, in inducing membrane domains [2,3]. We have previously
shown that the speciﬁc ligand binding activity of the serotonin1A
receptor displays an increase in membranes isolated from cholesterol-
depleted CHO-5-HT1AR cells [31]. Interestingly, we observe a similar
increase in ligand binding activity in the present work, in which
binding was monitored in membranes isolated from sphingomyeli-
nase treated cells. It remains to be explored whether the underlying
mechanism behind these effects is similar. For example, we have
previously shown that cholesterol depletion induces dynamic con-
ﬁnement of the serotonin1A receptor in the plasma membrane of
living cells [31,32]. It would be interesting to speculate whether such
dynamic rearrangement of the receptor could take place upon change
in cellular sphingomyelin/ceramide contents.
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